HKG Equity Snapshot
2592 Weekly Equity Report
Cloudbreak Pharma Inc.
What the company does
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated …
What the weekly tape is saying
2592 closed the latest completed week at 1.30 HKD. The 4-week return is -6.5% and the 12-week return is -30.5%. Trend Signal is inactive, Market Dynamics is -0.09. Setup signature: Risk-first tape with a 17/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 2.92 HKD
- Vs Trend Line
- -55.5%
- Fair Value
- 3.75 HKD
- Vs Fair Value
- -65.3%
- 52W High
- 9.74 HKD
- 52W Low
- 1.12 HKD
- Drawdown
- -86.7%
- Range Position
- 2.1%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 0
- 52W Active Breadth
- 0.0%
- Sector Scope
- HK Healthcare
- Sector Rank
- 21 of 257
- Sector Percentile
- 92.2%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
HK Healthcare
- Tracked Peers
- 100
- 4W Rank
- - of 100
- Avg 1W
- -1.3%
- Avg 4W
- -12.8%
- Trend Breadth
- 6.0%
- Positive MD
- 10.0%
HK Biotechnology
- Tracked Peers
- 76
- 4W Rank
- 11 of 76
- Avg 1W
- -1.6%
- Avg 4W
- -17.5%
- Trend Breadth
- 3.9%
- Positive RS
- 5.3%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- -0.09
- 4W MD Change
- -157.1%
- Relative Strength
- -
- 4W RS Change
- -
- Expectation
- Negative
- Probability
- 22.41%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 835.5K
- 13W Average
- 3.7M
- 52W Average
- 6.6M
- Vs 13W
- 0.2x
- Vs 52W
- 0.1x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 15.0%
- 52W Volatility
- 15.3%
- Upside Weeks
- 12
- Downside Weeks
- 35
- Downside Breadth
- 71.4%
- Avg Gain / Loss
- 14.0% / -7.6%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- HKG
- Country
- HK
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- HKD
- Market Cap
- 1.0B
Opportunity signals
- No strong opportunity cluster is confirmed yet; monitor trend and Market Dynamics.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Market Dynamics is negative, which weakens the current setup.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 1.30 HKD | 6.6% | 2.92 HKD | 3.75 HKD | -0.09 | - | 835.5K | Off |
| 5 Jun 2026 | 1.22 HKD | -5.4% | 3.02 HKD | 3.80 HKD | -0.06 | - | 2.2M | Off |
| 29 May 2026 | 1.29 HKD | -2.3% | 3.14 HKD | 3.85 HKD | -0.04 | - | 993.5K | Off |
| 22 May 2026 | 1.32 HKD | -5.0% | 3.25 HKD | 3.91 HKD | -0.04 | - | 831.5K | Off |
| 15 May 2026 | 1.39 HKD | -8.6% | 3.36 HKD | 3.96 HKD | -0.04 | - | 4.2M | Off |
| 8 May 2026 | 1.52 HKD | 2.7% | 3.47 HKD | 4.02 HKD | -0.20 | - | 1.6M | Off |
| 1 May 2026 | 1.48 HKD | -22.1% | 3.56 HKD | 4.08 HKD | -0.44 | - | 3.4M | Off |
| 24 Apr 2026 | 1.90 HKD | 41.8% | 3.66 HKD | 4.14 HKD | -0.68 | - | 7.6M | Off |
| 17 Apr 2026 | 1.34 HKD | -19.3% | 3.75 HKD | 4.19 HKD | -0.94 | - | 19.6M | Off |
| 10 Apr 2026 | 1.66 HKD | -2.9% | 3.87 HKD | 4.26 HKD | -1.04 | - | 1.5M | Off |
| 3 Apr 2026 | 1.71 HKD | 2.4% | 3.97 HKD | 4.33 HKD | -1.07 | - | 854.1K | Off |
| 27 Mar 2026 | 1.67 HKD | -10.7% | 4.08 HKD | 4.39 HKD | -1.07 | - | 2.0M | Off |
| 20 Mar 2026 | 1.87 HKD | -8.8% | 4.20 HKD | 4.46 HKD | -1.03 | - | 2.7M | Off |
| 13 Mar 2026 | 2.05 HKD | -6.0% | 4.30 HKD | 4.53 HKD | -0.99 | - | 1.3M | Off |